Jordan S. F. Chan

Jordan S. F. Chan

Auto-generated profile, based on publicly available information

Jordan S. F. Chan

Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB Canada; Alberta Diabetes Institute, University of Alberta, Edmonton, AB Canada; Cardiovascular Research Institute, University of Alberta, Edmonton, AB Canada; Women and Children's Health Research Institute, University of Alberta, Edmonton, AB Canada

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
AGAmanda A. Greenwell
Amanda A. Greenwell
SDSeyed amirhossein tabatabaei dakhili
Seyed amirhossein tabatabaei dakhili
CWCory S. Wagg
Cory S. Wagg
CSChristina T. Saed
Christina T. Saed
JCJordan S.F. Chan
Jordan S.F. Chan
JUJohn R. Ussher
John R. Ussher

13 May 2025 in Biochemical Journal
Verified
Journal Article
Open access
JCJordan S. F. Chan
Jordan S. F. Chan
TSTanin Shafaati
Tanin Shafaati
JUJohn R. Ussher
John R. Ussher
As the most metabolically demanding organ on a per gram basis, substrate metabolism in the heart is intricately linked to cardiac function. Virtually all major cardiovascular pathologies are associated with perturbations in cardiac substrate metabolism, and increasing evidence supports that these perturbations in substrate metabolism can directly contribute to cardiac dysfunction. Furthermore, type 2 diabetes (T2D) is a major risk factor for increased cardiovascular disease burden, while also being characterized by a very distinct metabolic profile in the heart. This includes increases in cardiac fatty oxidation rates and a robust reduction in cardiac glucose oxidation rates. Herein, we will describe the primary mechanisms responsible for the increase in cardiac fatty acid oxidation and decrease in cardiac glucose oxidation during T2D, while also detailing perturbations in cardiac ketone and amino acid metabolism. In addition, we will interrogate preclinical studies that have addressed whether correcting perturbations in cardiac substrate metabolism may have clinical utility against ischemic heart disease, diabetic cardiomyopathy, or heart failure associated with T2D. Lastly, we will consider the translational potential of such an approach to manage cardiovascular disease in people living with T2D.

1 November 2025 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
JCJordan S. F. Chan
Jordan S. F. Chan
LDLinyue Dong
Linyue Dong
JUJohn R. Ussher
John R. Ussher
Individuals living with obesity and/or type 2 diabetes (T2D) are at a disproportionately high risk of developing cardiovascular disease. This includes diabetic cardiomyopathy (DbCM), a condition characterized by left ventricular diastolic dysfunction that is often present in individuals with pre- or early-stage T2D. Although there are numerous mediators that contribute to the development of DbCM, perturbations in cardiac substrate metabolism are widely believed to play a major role in its pathogenesis. In particular, myocardial glucose oxidation is often suppressed due to decreased activity of the pyruvate dehydrogenase (PDH) complex, the rate-limiting enzyme of glucose oxidation, which is responsible for decarboxylating pyruvate to acetyl CoA, thus acting as the link between glycolysis and oxidative phosphorylation of glucose. Importantly, numerous preclinical studies suggest that restoring suppressed myocardial glucose oxidation can alleviate DbCM. In this review, we will describe the major perturbations that characterize myocardial substrate metabolism in T2D, while discussing the primary pharmacological approaches that have been pursued to stimulate myocardial PDH activity and glucose oxidation. We will also highlight potential mechanisms explaining how increasing myocardial PDH activity and glucose oxidation favorably influence diastolic function. Given the increasing prevalence of DbCM in the human population, it is not only imperative to better understand its pathophysiology but also to develop novel therapies for its management, which may also have utility in the management of heart failure with preserved ejection fraction.

16 July 2024 in Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
JCJordan S F Chan
Jordan S F Chan
TSTanin Shafaati
Tanin Shafaati
JUJohn R Ussher
John R Ussher
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like-peptide-1 (GLP-1) are incretin hormones that stimulate insulin secretion and improve glycemic control in individuals with type 2 diabetes (T2D). Data from several cardiovascular outcome trials for GLP-1 receptor (GLP-1R) agonists have demonstrated significant reductions in the occurrence of major adverse cardiovascular events in individuals with T2D. Although the cardiovascular actions attributed to GLP-1R agonism have been extensively studied, little is known regarding the cardiovascular consequences attributed to GIP receptor (GIPR) agonism. As there is now an increasing focus on the development of incretin-based co-agonist therapies that activate both the GLP-1R and GIPR, it is imperative that we understand the mechanism(s) through which these incretins impact cardiovascular function. This is especially important considering that cardiovascular disease represents the leading cause of death in individuals with T2D. With increasing evidence that perturbations in cardiac energy metabolism are a major contributor to the pathology of diabetes-related cardiovascular disease, this may represent a key component through which GLP-1R and GIPR agonism influence cardiovascular outcomes. Not only do GIP and GLP-1 increase the secretion of insulin, they may also modify glucagon secretion, both of which have potent actions on cardiac substrate utilization. Herein we will discuss the potential direct and indirect actions through which GLP-1R and GIPR agonism impact cardiac energy metabolism while interrogating the evidence to support whether such actions may account for incretin-mediated cardioprotection in T2D.

20 October 2026 in Canadian Journal of Diabetes
Verified
Journal Article
Open access
JCJordan S.F. Chan
Jordan S.F. Chan
CSChristina T. Saed
Christina T. Saed
RKRaven Kirschenman
Raven Kirschenman
CWCory S. Wagg
Cory S. Wagg
AKAlexa N. King
Alexa N. King
KGKeshav Gopal
Keshav Gopal
Type 2 diabetes (T2D) increases the risk for diabetic cardiomyopathy (DbCM), which is often characterized by diastolic dysfunction. Pre-menopausal women have a reduced incidence of both T2D and DbCM, but this disappears following menopause. Our goal was to evaluate the potential role for ovarian hormones in mediating these differences. The effect of ovariectomy (OVX) was investigated in female mice with experimental T2D following high-fat diet feeding for 12-weeks in combination with a low-dose treatment of streptozotocin at week 4. Body weight and body composition, glucose homeostasis, cardiac structure/function via ultrasound echocardiography, and myocardial substrate metabolism via isolated working heart perfusions were assessed. Sham and OVX female mice with T2D exhibited increases in body weight and fat mass, as well as impaired glucose homeostasis, though these parameters were more prominent in OVX than sham females when compared to their lean counterparts. However, only OVX female mice with T2D developed diastolic dysfunction as reflected by a significant decrease in the mitral E/A and tissue Doppler e'/a' ratios, as well as an increase in the E/e' ratio. Isolated working hearts from both sham and OVX female mice with T2D exhibited a reduction in glucose oxidation, though this was more pronounced in the latter. Lastly, only OVX female mice with T2D demonstrated cardiomyocyte hypertrophy. Our data illustrate key roles for ovarian hormones in impacting how T2D impacts the progression of DbCM in females, which may have relevance to women living with T2D as they transition to menopause.